FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...

GSK PLC GSK shares slipped 2.45% to £15.36 Friday, on what proved to be an all-around grim trading session for the stock ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small ...

Coca-Cola Co. plans to inject $1 billion investment in Nigeria over the next five years, motivated by ongoing reforms ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Climate Asset Management, the natural capital joint venture between HSBC Asset Management and Pollination, has reached a ...

Fierce Pharma’s Andrea Park and Ben Adams talk about major trends from the event that came up in conversations, including the ...